Insights

Executive Summary: The Structural Redesign of an Industry The pharmaceutical sector, historically characterized by its defensive moats of intellectual property

Section 1: The Economic Architecture of Modern Drug Development The numbers that define pharmaceutical R&D productivity are brutal and well-documented.

Introduction China’s pharmaceutical sector completed a structural transformation in less than a decade. The country that was processing the world’s

Part 1: What Branded Generics Are (and Why the Distinction Matters) Defining the Category A branded generic is a pharmaceutical

Section 1: Why API Strategy Is Corporate Strategy The Active Pharmaceutical Ingredient is not a line item in a chemistry

Key Takeaways (Executive Summary) Part I: The BPCIA Framework — Why ‘Abbreviated’ Is a Misnomer What the Biologics Price Competition

Executive Summary As of January 2026, the United States biosimilars market stands at a critical juncture, characterized by a fundamental

The path from discovery to commercial dominance has never been more expensive, more legally treacherous, or more dependent on intelligence